Our Portfolio
LDD works with innovative life sciences, medical device and medical technology companies in Utah and Asia. Our hands-on approach helps to strategically accelerate growth, with measurable milestones that ensure the right trajectory.
U.S. Portfolio
Promotus, an early-stage medical device company, has developed KneeMD, a patient-controlled rehabilitation device designed to facilitate improved range of motion in patients following total knee replacement, as well as other major knee surgeries and injuries. A clinical trial of KneeMD is currently underway at Anne Arundel Medical Center.
Ice Boa is an early-stage medical device company that has developed a novel cryotherapy system with a high-power, patient-controlled compression reel. Their first product is designed to provide cost-effective cold compression to the knee, but their technology can also be applied to cold compression products for the ankle, hip, shoulder, wrist and elbow.
International Portfolio
Ultra V, a medical aesthetics and medical device company, has developed a non-surgical facelift technology using resorbable sutures that stimulate natural collagen synthesis. Already gaining traction in Asia and Europe, Ultra V is currently seeking FDA 510(k) clearance to launch in the US market.
Gencurix is a molecular diagnostics company focused on developing cancer prognosis, companion diagnostic and liquid cancer detection products. Their first product is GenesWell™BCT, an assay for determining risk of recurrence in early stage breast cancer. Gencurix is currently focused on conducting a clinical validation study of GenesWell™BCT in preparation for FDA 510(k) submission.
Abion specializes in the development of innovative companion diagnostics-based new drugs that target the best-in-class / first-in-class categories of the global market. Their first candidate drug, a c-Met inhibitor is targeted at cancers with abnormal kinase activation.
PeopleBio specializes in developing diagnostics for protein misfolding diseases using its proprietary platform technology, Multimer Detection System (MDS), a sandwich assay for precise detection of oligomers or multimers in protein misfolding diseases. Their first product—inBlood™ OAß—detects amyloid-beta oligomers and is designed to help diagnose and monitor Alzheimer’s disease.